SEC Filing Summary
Filing identity: The supplied filing is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013—not a filing under the name Alaunos Therapeutics, Inc. Investors should verify the issuer and period.
Business context and reporting period
ZIOPHARM described itself as a development-stage biopharmaceutical company focused on cancer therapies. It had no approved products and had generated only minimal revenue. The filing reports results for the three months ended March 31, 2013, compared with the same 2012 period.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Revenue | $0.2 million | $0.2 million |
| Research and development expense | $19.1 million | $14.0 million; up 37% |
| General and administrative expense | $4.7 million | $4.8 million; down 4% |
| Operating loss | $23.6 million | $18.6 million |
| Net loss | $12.8 million | $24.5 million |
| Net loss per share | $0.15 | $0.32 |
| Cash used in operations | $18.2 million | $25.9 million |
The lower net loss chiefly reflected a $10.8 million noncash gain from the change in fair value of warrant liabilities; the comparable 2012 period included a $5.8 million warrant-related loss. The operating loss therefore increased despite the lower reported net loss.
At March 31, 2013, cash and cash equivalents were $55.7 million, down from $73.3 million at December 31, 2012. Working capital was $40.2 million, versus $61.4 million at year-end. Total liabilities were $25.5 million, including $2.2 million of warrant liabilities; the presented balance sheet reports no borrowings. Total contractual obligations were $7.1 million, mainly operating leases.
Cash used in investing activities was $0.1 million. Financing provided $0.7 million, primarily from option and warrant exercises, versus $49.3 million in Q1 2012, which included public-offering proceeds. Cash declined by $17.7 million during Q1 2013.
Material changes and business developments
- On March 26, the company reported that its Phase 3 PICASSO 3 trial of palifosfamide in first-line metastatic soft tissue sarcoma did not meet its primary progression-free-survival endpoint. It decided to terminate development in that indication.
- The company shifted strategic focus to its Intrexon-partnered synthetic biology cancer programs, including DC-RTS-IL-12 and Ad-RTS-IL-12. A Phase 2 Ad-RTS-IL-12 melanoma study had begun; management expected data in the second half of 2013. A Phase 2 breast-cancer study combining Ad-RTS-IL-12 with palifosfamide had also started.
- The MATISSE Phase 3 palifosfamide small-cell lung cancer trial had enrolled 188 patients when enrollment was suspended following the PICASSO 3 outcome. The filing forecast an overall-survival interim analysis in the first half of 2014.
- R&D expense rose by $5.1 million year over year, principally because of higher small-cell lung cancer trial costs and manufacturing activity. Q1 expenses included $4.3 million in PPD milestones, $2.2 million in PRA milestones, and $0.1 million in Novella milestones.
Outlook, risks, and unusual items
Management estimated that existing cash would fund operations into the first quarter of 2014, based on its plans and assumptions. It expected continuing losses and said additional financing would be needed for longer-term clinical development. The company had no committed additional capital and cautioned that financing might be unavailable or dilutive. The filing states that the independent auditor had expressed substantial doubt about the company’s ability to continue as a going concern.
After quarter-end, on April 3, the company implemented a workforce reduction eliminating 65 positions, including 40 filled roles. It expected $1.6–$1.8 million of primarily severance charges in Q2 2013 and was still evaluating potential facility exit costs.
Key risks include clinical-trial failure or delay, inability to raise capital, uncertainty and expense in developing synthetic biology products, dependence on Intrexon and contract research/manufacturing providers, regulatory and intellectual-property risks, and the absence of product revenue. Management reported disclosure controls as effective and no material change in internal control over financial reporting during the quarter. It reported no legal matter expected to have a material adverse effect as of March 31.
Important facts for investors to verify
- Confirm the issuer: the filing names ZIOPHARM Oncology, Inc., while the request identifies Alaunos Therapeutics, Inc.
- Review the full PICASSO 3 results and implications, and confirm subsequent status of the suspended MATISSE trial and other palifosfamide programs.
- Assess the assumptions underlying the stated cash runway into Q1 2014, subsequent cash use, and availability and terms of financing.
- Check the actual restructuring charges and any facility-related costs recorded after quarter-end.
- Distinguish operating performance from the substantial noncash warrant fair-value gain that reduced the reported net loss.